deltatrials
Completed PHASE3 NCT03552757

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes

Sponsor: Novo Nordisk A/S

Conditions Obesity Overweight
Interventions Placebo I (Semaglutide) Placebo II (Semaglutide) Semaglutide 1.0 mg Semaglutide 2.4 mg
Updated 22 times since 2018 Last updated: Nov 8, 2021 Started: Jun 4, 2018 Primary completion: Mar 24, 2020 Completion: May 1, 2020

A PHASE3 clinical study on Obesity and Overweight, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 22 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Sep 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 17 earlier versions

  1. Apr 2021 — Sep 2021 [monthly]

    Completed PHASE3

  2. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE3

  3. Jul 2020 — Jan 2021 [monthly]

    Completed PHASE3

  4. Jun 2020 — Jul 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Feb 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  11. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  12. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  13. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  14. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  15. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  16. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  17. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novo Nordisk A/S
Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Almería, Spain , Alpharetta, United States , Anderson, United States , Athens, Greece , Atlanta, United States , Austin, United States , Bangalore, India , Barnaul, Russia , Bristol, United States and 110 more locations